Organon Beats On Q1, Women's Health Leads the Charge
Organon Beats On Q1, Women's Health Leads the Charge
Organon & Co (NYSE:OGN) reported a 5% Y/Y increase in the first quarter of 2024 revenue, reaching around $1.622 billion, beating the consensus of $1.563 billion.
Organon & Co（紐約證券交易所代碼：OGN）報告稱，2024年第一季度收入同比增長5％，達到約16.22億美元，超過市場預期的15.63億美元。
Women's Health revenue increased by 11% as reported and 12% ex-FX, driven by 34% ex-FX growth in Nexplanon led by favorable customer purchasing patterns associated with the timing of U.S. list-price adjustments, coupled with favorable price and discount rates in the U.S. and the favorable timing of tenders to markets outside of the U.S.
報告顯示，女性健康收入增長了11％，扣除外匯收入增長了12％，這得益於Nexplanon34％的外匯前增長，這得益於與美國上市價格調整時機相關的有利客戶購買模式，加上美國有利的價格和折扣率以及向美國以外市場進行招標的有利時機。
Biosimilar revenue surged by 46% reported and ex-FX, aided by Ontruzant, which benefited from incremental demand from a tender in Brazil and Renflexis, which gained from continued demand growth in the U.S and Canada.
在Ontruzant的幫助下，公佈的生物仿製藥收入激增了46％，前者受益於巴西和Renflexis的招標需求增加， 這得益於美國和加拿大的需求持續增長。
Established Brands remained flat Y/Y on an as-reported basis and grew 2% Y/Y ex-FX as contribution from the recent licensing of Emgality and Rayvow along with a recovery in certain injectable steroid products following last year's market action offset the impacts of Volume Based Procurement initiatives in China.
據報告，知名品牌同比持平，除外匯外，同比增長2％，這要歸因於Emgality和Rayvow最近獲得的許可，以及去年市場行動之後某些注射類固醇產品的復甦，抵消了中國批量採購計劃的影響。
For the first quarter, Organon reported an adjusted gross margin of 62.1% vs. 65.2% a year ago.
Organon報告稱，第一季度調整後的毛利率爲62.1％，去年同期爲65.2％。
Adjusted EBITDA margin contracted to 33.2% from 33.7% in the prior year quarter due to cost containment initiatives targeting operating expenses.
由於針對運營開支的成本控制舉措，調整後的息稅折舊攤銷前利潤率從上一季度的33.7％收縮至33.2％。
The company reported adjusted EPS of $1.22, beating the consensus of $0.93.
該公司報告調整後的每股收益爲1.22美元，超過市場預期的0.93美元。
As of March-end, cash and cash equivalents were $575 million, and debt was $8.7 billion.
截至3月底，現金及現金等價物爲5.75億美元，債務爲87億美元。
Dividend: The Board of Directors declared a quarterly dividend per sharer of $0.28, payable on June 13 to stockholders of record as of May 13.
股息：董事會宣佈每股季度股息爲0.28美元，將於6月13日支付給截至5月13日的登記股東。
FY24 Guidance Reaffirmed: It forecasts revenue of $6.2 billion-$6.5 billion versus the consensus of $6.37 billion and adjusted EBITDA margin of 31.0%-33.0%.
重申24財年指導方針：它預測收入爲62億至65億美元，而市場普遍預期爲63.7億美元，調整後的息稅折舊攤銷前利潤率爲31.0％-33.0％。
Investors can gain exposure to the stock via SPDR S&P Pharmaceuticals ETF (NYSE:XPH) and Invesco S&P SmallCap Health Care ETF (NASDAQ:PSCH).
投資者可以通過SPDR標普製藥ETF（紐約證券交易所代碼：XPH）和景順標普小型股醫療保健ETF（納斯達克股票代碼：PSCH）獲得股票敞口。
Price Action: OGN shares are up 2.18% at $19.24 at the last check Thursday.
價格走勢：在週四的最後一次檢查中，OGN股價上漲2.18％，至19.24美元。
Photo via Shutterstock
照片來自 Shutterstock